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Abstract 
Triapine, the most prominent anticancer drug candidate from the substance class of 
thiosemicarbazones, was investigated in more than 30 clinical phase I and II studies. 
However, the results were rather disappointing against solid tumors, which can be 
explained (at least partially) due to inefficient delivery to the tumor site. Hence, we 
synthesized the first biotin-functionalized thiosemicarbazone derivatives in order to 
increase tumor specificity and accumulation. Additionally, for Triapine and one biotin 
conjugate the iron(III) and copper(II) complexes were prepared. Subsequently, the novel 
compounds were biologically evaluated on a cell line panel with different biotin uptake. 
The metal-free biotin-conjugated ligands showed comparable activity to the reference 
compound Triapine. However, astonishingly, the metal complexes of the biotinylated 
derivative showed strikingly decreased anticancer activity. To further analyze possible 
differences between the metal complexes, detailed physico- and electrochemical 
experiments were performed. However, neither lipophilicity or complex solution stability, 
nor the reduction potential or behavior in the presence of biologically relevant reducing 
agents showed strong variations between the biotinylated and non-biotinylated 
derivatives (only some variations in the reduction kinetics were found). Nonetheless, the 
metal-free biotin-conjugate of Triapine revealed distinct activity in a colon cancer mouse 
model upon oral application comparable to Triapine. Therefore, this type of biotin-
conjugated thiosemicarbazone is of interest for further synthetic strategies and 
biological studies. 
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Introduction 
Since several decades, α-N-heterocyclic thiosemicarbazones have been investigated 
for their potential as anticancer therapeutics[1, 2]. As biological target ribonucleotide 
reductase (RR) has been proposed, a metalloenzyme catalyzing the conversion of 
ribonucleotides to 2’-deoxyribonucleotides, making it essential for DNA synthesis and 
repair[3]. In fact, thiosemicarbazones are the strongest known inhibitors of this enzyme 
being several orders of magnitude more efficient than hydroxyurea, the first clinically 
approved RR inhibitor[4, 5]. While the exact mode of action of thiosemicarbazones is 
still unknown, they most likely bind intracellular iron via their NNS-donor atoms. It is 
assumed that the resulting iron complex interacts with the RR and as a consequence 
disturbs DNA synthesis. Moreover, complexation of other biologically relevant metals 
such as copper has been discussed to be important for the mode of action of (at least 
some) thiosemicarbazones, since their mono-ligand copper(II) complexes have proven 
exceptionally high stability[6, 7]. The clinically most prominent representative of the 
substance class of thiosemicarbazones is 3-aminopyridine-2-carboxaldehyde 
thiosemicarbazone (Triapine) which has already been evaluated in more than 30 clinical 
phase I and II studies[8-11]. While Triapine was activity against leukemia, there was no 
effect against solid cancers such as non-small-cell lung cancer[12] or renal cell 
carcinoma[13]. The exact reasons for the inefficacy of Triapine monotherapy against 
solid tumors are still unknown but might be fast metabolism/excretion[14] and/or 
ineffective drug delivery[15, 16]. Thus, novel strategies to increase tumor accumulation 
and specificity of thiosemicarbazones are of high interest.  
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Notably, also di(2-pyridyl)ketone thiosemicarbazones, such as di(2-pyridyl)ketone-4,4-
dimethyl-3-thiosemicarbazone (Dp44mT)[17] or the cyclohexyl-analoque di-2-
pyridylketone-4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC)[18] have shown 
promising anticancer activity in numerous preclinical studies. Excitingly, DpC recently 
entered clinical phase I trials for treatment of advanced solid tumors (NCT02688101) 
and additionally another novel thiosemicarbazone, 4-(2-pyridinyl)-2-(6,7-dihydro-8(5H)-
quinolinylidene)hydrazide (COTI-2) is currently undergoing phase I evaluation for 
treatment of advanced or recurrent gynecologic malignancies (NCT02433626). 
A promising approach to enhance tumor targeting is the so-called active targeting 
approach. In this strategy, a tumor-targeting moiety which selectively binds to receptors 
that are overexpressed in cancer cells is conjugated to the drug. Prominent examples 
are vitamins like folic acid[19, 20], biotin[21] or sugars[22]. Notably, glycoconjugation of 
thiosemicarbazones, targeting the increased expression of glucose transporters in 
colorectal cancer cells, has been described previously[23]. The biotin moiety is one of 
the best investigated targeting ligands with several literature examples proving evidence 
of its beneficial properties[24-26]. Biotin, which is also known as vitamin B7 or 
coenzyme R, is an essential growth promotor at cellular level and works as a coenzyme 
for carboxylase enzymes in the preparation of fatty acids, valine and isoleucine. 
Additionally, it plays essential roles in cell signaling and epigenetic gene regulation[27]. 
The main transporter for biotin is the sodium-dependent multivitamin transporter 
(SMVT). While the biotin transport is widely referred to as Na+-dependent[28], the exact 
mechanism is still in discussion and several modes of action have been proposed e.g. 
via ligated intestinal loops or isolated enterocytes[29]. Since the SMVT is 
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overexpressed in a broad range of cancer cell lines, biotin conjugates are taken up 
preferentially by these cells[30]. Consequently, functionalization of thiosemicarbazones 
with the biotin moiety should enhance cellular uptake and lead to accumulation in the 
tumor tissue.  
In this study, we synthesized several biotin-thiosemicarbazone conjugates and 
evaluated the biological activity on a panel of biotin-expressing cancer cell lines to 
select the most promising candidate. Furthermore, metal complexes of this derivative 
with the biologically relevant metals ions iron(III) and copper(II) were synthesized and 
evaluated regarding their anticancer activity, physico- and electrochemical properties, 
and their interaction with relevant antioxidants. Additionally, in vivo experiments using 
CT-26 colon cancer-bearing mice were performed with biotin-conjugated Triapine.  
Results 
 
Synthesis and characterization 
For conjugation of anticancer thiosemicarbazones to biotin three different derivatives 
were synthesized (Scheme 1): 1) Triapine conjugated via a butylene linker 
(BioTriapine), 2) 2-formylpyridine thiosemicarbazone (FTCS) conjugated via an 
ethylene linker (BioFTSC1) and 3) FTSC conjugated via a butylene linker (BioFTSC2). 
All derivatives were synthesized starting from the mono-tert-butyloxycarbonyl (BOC)-
protected diamines, which were treated with CS2, CH3I and N2H4·H2O to the 
thiosemicarbazides. Subsequent condensation with the respective aldehyde and 
deprotection using conc. HCl generated the linker-containing thiosemicarbazones (4a-
c)[31]. Finally, the NHS-ester of biotin was conjugated to obtain the desired biotin-
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conjugated thiosemicarbazone derivatives BioTriapine, BioFTSC1 and BioFTSC2 with 
yields between 66 % and 84 %. 
 
 
Scheme 1: Synthesis of the biotin-conjugated thiosemicarbazone derivatives BioTriapine, BioFTSC1 
and BioFTSC2 
 
For BioTriapine, additionally, the respective copper(II) and iron(III) complexes were 
synthesized. In case of the copper complex, a 1:1 metal-ligand ratio was chosen (Figure 
1) due to the generally low aqueous solubility of 1:2 complexes of the type [Cu(L2)] (L 
representing mono-deprotonated thiosemicarbazone) and their tendency to at least 
partially dissociate into the corresponding 1:1 complexes at biologically relevant 
concentrations [32]. Reaction of BioTriapine with CuCl2·2H2O in MeOH at 1:1 ratio 
resulted in the formation of [Cu(BioTriapine)Cl2]·H2O (Cu-BioTriapine) in 81% yield. 
Negative ion electrospray ionization (ESI) mass spectra of this complex display a strong 
8 
 
main signal of [M-2H-Cl]- at m/z 588, as well as the  [M-H]- signal at m/z 624, while in 
the positive mode the peak of [M-2Cl-H]+ was found at m/z 554. 
The iron complex [Fe(BioTriapine)2]NO3 (Fe-BioTriapine) was synthesized starting 
from Fe(NO3)3·9H2O and BioTriapine in methanol in the presence of N-
methylmorpholine. In case of iron(III) the bis complex was prepared to saturate the 
typical octahedral coordination sphere of this metal ion. Subsequent purification via RP-
HPLC resulted in [Fe(BioTriapine)2]NO3·3.5H2O with 42% yield. Positive ion ESI mass 
spectra for this complex show a sharp [M]+ signal at m/z 1038. Fe-Triapine and Cu-
Triapine were synthesized as described previously[33, 34]. 
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Figure 1: Chemical structures of the novel biotin-conjugated metal complexes Fe-BioTriapine and Cu-
BioTriapine, as well as the reference compounds Fe-Triapine and Cu-Triapine. 
 
Anticancer activity of the new compounds in cell culture after 72 h drug exposure 
As a first step, an appropriate cell line panel for the testing of our novel biotin-
conjugated compounds was selected. Thus, several cell lines were starved for 24 h 
followed by treatment with FITC-labeled biotin (25 µM) for 6 h and analyzed on their 
fluorescence intensity by flow cytometry (Figure 2). In line with available literature[35], 
MCF7 cells showed exceptionally high in biotin uptake, while SKBR-3 and MDA-MB-231 
had medium biotin accumulation. HCT116 cells served as negative uptake control.  
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Figure 2. Uptake of FITC-labeled biotin in the cell line panel used in this study. The indicated cell lines 
were serum-starved for 24 h, followed by treatment with 25 µM FITC-labeled biotin for 6 h. Fluorescence 
was detected by flow cytometry. Values shown are means and standard deviation of three samples. 
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This cell line panel was then tested for their sensitivity against the biotin-conjugated 
thiosemicarbazones in comparison to the respective parental drugs (Table 1). With 
regard to the non-biotinylated drugs Triapine and FTSC, in general, all cell lines were 
similarly sensitive with an IC50 of ~ 1 µM and 3.5 µM, respectively. Only SKBR-3 cells 
were more resistant with a ~5-fold and 8-fold increased IC50 value, respectively. Also 
Fe-Triapine and Cu-Triapine widely followed this trend. With regard to the impact of 
biotin conjugation, no clear trends were visible. Thus, in case of BioTriapine, HCT116, 
MDA-MB-231 and MCF-7 have an IC50 value of ~ 3 µM. This would indicate that biotin-
conjugation slightly decreases the anticancer activity of Triapine. However, in the 
thiosemicarbazone-resistant SKBR-3 model biotinylation of Triapine distinctly enhanced 
its efficacy. Interestingly, the comparison of BioFTSC1 and BioFTSC2 indicated that 
the chosen linker system strongly influences the anticancer activity, as the ethylene 
linker-containing derivative (BioFTSC1) was far less effective than the butylene linker-
containing compounds (BioFTSC2 and BioTriapine). With regard to the impact of 
metal coordination, highly unexpected results were obtained. Thus, Cu(II) as well as 
Fe(III) coordination strongly diminished the activity of BioTriapine. In case of Cu(II) 
complexation, especially in the SKBR-3 and MCF-7 cell line, up to ~30 fold reduced 
activity of BioTriapine was observed, in comparison Triapine complexation resulted in 
an only up to ~5 fold decrease. In HCT116 cells, the copper complexation of Triapine 
induced a stronger activity decrease as compared to BioTriapine. With regard to Fe-
BioTriapine, the differences were even more striking with a complete inactivation up to 
the highest tested concentration of 100 µM in all cell lines, in strong contrast to Fe-
Triapine with IC50 values of ~5 µM. Additionally, the activity of none of the new biotin-
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conjugated compounds followed the uptake of FITC-labeled biotin in the initial 
experiments (compare Figure 2). A similar activity pattern was observed in the murine 
colon carcinoma CT-26 cell line, our routine screening model for subsequent in vivo 
studies (see below). In contrast, the non-malignant human fibroblasts HLF were much 
less sensitive to the compounds compared to most of the tested cancer cell models. 
Table 1: IC50 values of the new compounds in comparison to Triapine and FTSC references after 72 h 
incubation. The compounds were tested in the indicated cell lines via MTT-based viability assays. The 
means of the IC50 values (expressed in µM) were calculated from at least two experiments. 
Cell line HCT116 
MDA-MB-
231 SKBR-3 MCF-7 CT26 HLF 
Biotin Uptake low medium medium high n.t. n.t. 
   IC₅₀ ± SD   IC₅₀ ± SD  IC₅₀ ± SD   IC₅₀ ± SD  IC₅₀ ± SD  IC₅₀ ± SD  
Triapine 0.8 ± 0.4 1.5 ± 1.1 8.8 ± 0.6 1.0 ± 0.1 0.8 ± 0.2 > 10 
BioTriapine 3.6 ± 0.1 3.2 ± 0.8 0.7 ± 0.3 2.9 ± 0.9 4.1 ± 1.2 7.6 ± 1.1 
Cu-Triapine 7.8 ± 0.04 4.8 ± 0.2 6.5 ± 2.5 4.7 ± 0.1 5.2 ± 1.1 > 25 
Cu-BioTriapine 19.3 ± 3.7 18.3 ± 0.8 19.1 ± 1.0 37.4 ± 4.5 > 100 > 100 
Fe-Triapine 4.1 ± 0.8 3.9 ± 0.6 6.9 ± 2.6 4.4 ± 0.02 1.7 ± 1.0 4.3 ± 0.3 
Fe-BioTriapine > 100 > 100 > 100 > 100 > 100 > 100 
FTSC 
3.2 ± 
0.002 3.6 ± 0.8 16.1 ± 1.3 3.9 ± 0.3 2.9 ± 0.9 > 25 
BioFTSC1 31.4 ± 3.6 10.8 ± 0.7 63.2 ± 2.8 42.3 ± 8.6 > 75 56.1 ± 8.0 
BioFTSC2 2.0 ± 0.3 8.6 ± 1.4 2.8 ± 0.4 2.7 ± 0.9 > 10 > 10 
 
Anticancer activity of oral BioTriapine against murine CT26 colon carcinoma in 
vivo 
In parallel to the cell culture experiments, first in vivo tests of BioTriapine were 
performed using CT-26 colon carcinoma-bearing mice. To this end, murine CT26 cells 
were injected into the right flank of Balb/c mice and oral treatment with BioTriapine (25 
mg/kg) was started when the tumors were palpable. Therapy was well tolerated which 
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was also indicated by a stable body weight during treatment (data not shown). As 
shown in Figure 3, BioTriapine significantly retarded the tumor growth of CT-26 cells 
comparable to the reference compound Triapine. 
 
Figure 3. Anticancer activity in vivo. Murine CT-26 cells (5  10
5 
cells in 50 µL) were injected 
subcutaneously into the right flank of Balb/c mice. Animals were treated with BioTriapine or Triapine 
orally (25 mg/kg in 10% DMSO) on days 3-7 and 10-14. Tumor size was assessed regularly by caliper 
measurement. Number of animals is 4 per group. (A) Tumor volumes (means ± standard errors of the 
mean, SEM), calculated using the formula: length × width
2
 / 2. Tumors in BioTriapine-treated animals 
were significantly smaller in comparison to solvent-treated animals on day 17; two-way ANOVA *** 
p<0.001. (B) Overall survival of the BioTriapine-treated animals was significantly prolonged; Mantel-Cox 
test *p<0.05. 
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Impact of biotinylation on uptake of Cu-BioTriapine vs. Cu-Triapine and CuCl2 
Based on the distinctly decreased activity of the metal complexes of BioTriapine, we 
hypothesized that this could be based on reduced uptake of the biotinylated 
compounds. Consequently, to gain more insights into this issue, cellular copper levels of 
HCT116 and MCF7 cells were evaluated after treatment with Cu-BioTriapine, Cu-
Triapine or CuCl2 for 4 h using inductively coupled plasma mass spectrometry (ICP-
MS; the measurement of the iron complexes was not possible due to the high 
environmental background levels of iron). Interestingly, although untreated HCT116 had 
slightly higher intrinsic levels of copper than MCF-7 cells, both cell models accumulated 
CuCl2 to comparable extent (Figure 4). In general, MCF-7 cells were more active with 
regard to the uptake of both Cu thiosemicarbazones in comparison to HCT116 cells. 
Thus, in agreement with the viability data, biotin uptake levels (Figure 2) did not 
correlate with the intracellular levels of Cu-BioTriapine. At lower drug concentrations 
(25 µM), biotinylation of Cu-Triapine resulted in reduced intracellular levels, while at 50 
µM there was a tendency for higher Cu-BioTriapine uptake compared to Cu-Triapine. 
In summary, there was no clear-cut trend between the two thiosemicarbazone, which 
could serve as explanation for the ~ 10-fold difference in IC50 value between these two 
drugs in MCF7 cells.  
To evaluate the role of the SMVT in the drug uptake of our cancer cells, inhibition 
experiments using the SMVT inhibitor indomethacine were performed[36]. In contrast to 
the FITC-labelled biotin, where indomethacine treatment distinctly reduced uptake in 
MCF-7 but not HCT-116 cells, the inhibitor was not able to prevent the cellular 
accumulation of Cu-BioTriapine (or Cu-Triapine) (Figure 5). 
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This, on the one hand, indicates that the biotinylation of Cu-Triapine does not result in 
enhanced uptake in cells with higher biotin uptake and, on the other hand, does not 
explain the reduced activity of these drugs against cancer cells.  
 
Figure 4. Cellular uptake of copper compounds. Cells were treated with Cu-Triapine, Cu-BioTriapine or 
CuCl2 (25 µM or 50 µM) and incubated for 4 h at 37°C. Intracellular copper levels were detected by ICP-
MS measurements. 
 
15 
 
Figure 5. Impact of the SMVT inhibitor indomethacine on uptake of FITC-biotin and Cu-BioTriapine. The 
indicated cell lines were treated with A) FITC-biotin or B) Cu-Triapine and Cu-BioTriapine (25 µM) with 
and without 1 mM indomethacine (IM) and incubated for 4 h at 37°C. Uptake was measured by flow 
cytometry and ICP-MS, respectively. 
 
Impact of long-term exposure on the anticancer activity of biotin 
thiosemicarbazone derivatives  
Since the strong impact of biotinylation on the effectivity of metal-containing 
thiosemicarbazones could not be explained by changes in the cellular uptake, we 
hypothesized that the compounds need longer exposure time in order to get activated in 
a redox-dependent manner. Consequently, we wanted to know whether prolonged 
exposure time results in enhanced efficacy of the compounds. To this end, clonogenic 
assays with 9 days of exposure were performed in HCT116 and MCF7 cells. 
As shown in Table 2, prolonged exposure time in general resulted in enhanced activity 
of the drugs against both cell models. Moreover, the increase in activity compared to the 
72 h experiment was similar in both cell lines for Triapine, BioTriapine, Cu-Triapine 
and Fe-Triapine. However, in case of the biotinylated metal complexes distinct 
differences were observed: while Cu-BioTriapine was comparably active in MCF7 cells 
after 3 days and 9 days of exposure, the compounds distinctly lost their activity upon 
prolonged incubation time in HCT116 cells. In contrast, Fe-BioTriapine was distinctly 
activated by prolonged exposure time, especially in the MCF7 cells, however could by 
far not reach the levels of Fe-Triapine.  
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Table 2. IC50 values of the thiosemicarbazone compounds after 9 days of incubation. The compounds 
were tested in the indicated cell lines via clonogenic assays. The means of the IC50 values (expressed in 
µM) were calculated from at least two experiments. The table also shows a comparison of the results to 
the short term viability assays with 72 h incubation. 
 
HCT116 MCF-7  
 
IC₅₀ ± SD increase to 72 h IC₅₀ ± SD increase to 72 h 
                 
Triapine 0.4 ± 0.04 2.0-fold 0.4 ± 0.1 2.5-fold 
BioTriapine 0.6 ± 0.2 6.0-fold 0.7 ± 0.1 4.1-fold 
Cu-Triapine 1.6 ± 0.2 4.9-fold 0.9 ± 0.1 5.2-fold 
Cu-BioTriapine > 40 < 0.5-fold 31.7 ± 1.3 1.2-fold 
Fe-Triapine 0.9 ± 0.02 4.6-fold 1.0 ± 0.1 4.4-fold 
Fe-BioTriapine 62.8 ± 2.1 > 1.7-fold 28.8 ± 3.5 > 3.7-fold 
 
 
Comparison of pKa values and lipophilicity of Triapine and BioTriapine  
Due to the surprisingly strong differences in the activity of the metal complexes of 
BioTriapine compared to the reference complexes of Triapine alone (especially the 
remarkably low activity of Fe-BioTriapine), we were interested if the metal complexes 
of Triapine and BioTriapine show different physico-chemical properties that might 
explain their different biological behaviour.  
First of all the solution equilibrium properties of BioTriapine were studied in pure 
water using UV-visible (UV-vis) spectrophotomeric titrations. For adequate comparison, 
measurements were also performed for Triapine and its complexes under identical 
conditions (the proton dissociation processes of Triapine and its complexation with 
copper(II) and iron(III) ions were already reported in our previous works[7, 37], however, 
these measurements were performed in a 30% (w/w) DMSO/H2O solvent mixture). The 
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pKa values of the ligands (Table 3) were determined by the deconvolution of UV-vis 
spectra recorded in the pH range from 2 to 11.5. As expected, characteristic changes 
were seen in the UV-vis spectra of the ligands due to the deprotonation processes as 
shown for BioTriapine in Figure 6. Triapine and BioTriapine possess two dissociable 
protons, namely at the pyridinium (NH+) nitrogen (pK1) and the hydrazinic (NH) nitrogen 
of the thiosemicarbazide moiety (pK2). In the latter deprotonation step the negative 
charge is mainly localized on the sulfur atom due to the thione–thiol tautomeric 
equilibrium in the completely deprotonated form of the ligands.  
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Figure 6. (A) UV-vis spectra of BioTriapine recorded at various pH values and (B) concentration 
distribution curves for the ligand species with the absorbance values at 400 nm.  [cL = 74 µM; pH = 2 ‒ 
11.5; T = 25 ˚C; I = 0.10 M (KCl); ℓ = 1.0 cm] 
 
Comparing the proton dissociation constants of the ligands (Table 3) it can be 
concluded that the N-terminally biotin derivatization results in somewhat elevated pKa 
values. In comparison to Triapine, especially pK2 is higher due to the close proximity of 
the electron donating biotin methylene groups to the deprotonating thiosemicarbazide 
moiety. Both ligands are charge-neutral (in HL form) at physiological pH. Notably, the 
lipophilicity of BioTriapine, expressed as n-octanol-water distribution coefficient at pH 
7.4, is just slightly higher compared to that of Triapine (see logD7.4 values in Table 3). 
 
Solution stability of the copper(II) and iron(III) complexes of Triapine and 
BioTriapine 
In order to characterize the aqueous solution behavior of Cu-BioTriapine and 
Cu-Triapine, they were dissolved in an acidic solution and titrated by strong base while 
their UV-vis spectra were recorded (see representative spectra for Cu-BioTriapine in 
Figure S1A). For both thiosemicarbazone complexes, the spectra revealed two well-
separated equilibrium processes with increasing pH. Based on the findings reported in 
the presence of 30% (w/w) DMSO for the copper(II)-Triapine system[7], the first step in 
the acidic pH range is most likely the deprotonation of the complex [CuLH]2+. Then the 
mixed hydroxido species [CuL(OH)] is formed from [CuL]+ in the basic pH range. 
Therefore, pKa values of [CuLH]
2+ and [CuL]+ complexes were determined by the 
spectral data evaluation (Table 3) in addition to the individual spectra of the complexes 
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(Figure 6B). The pKa values of the complexes are in the same range as reported by 
Antholine et al. in the case of 2-formylpyridine thiosemicarbazone (FTSC) (pKa = 2.40 
and 8.30) in aqueous solution (with 1% DMSO)[38].  
 
Table 3. pKa and logD7.4 values of Triapine and BioTriapine and their various copper(II) complexes 
determined by spectrophotometric titrations, conditional (logβ’) stability constants for [CuL]
+
 species at pH 
5.90 determined via EDTA displacement reaction and overall stability constants (logβ) in addition to pCu 
values and fractions of [CuL(OH)] at pH 7.4 (logβ) [t = 25 
○
C, I = 0.10 M (KCl)]. 
 
 Triapine BioTriapine 
pKa (H2L
+) 4.25±0.01 4.39±0.02 
pKa (HL) 10.58±0.01 11.10±0.02 
pKa [CuLH]
2+ 2.51±0.08 2.55±0.08 
pKa [CuL]
+ 8.64±0.08 8.71±0.06 
logβ’5.9 [CuL]
+ a 12.88±0.06 12.97±0.07 
logβ [CuLH]2+ b 20.08 20.73 
logβ [CuL]+ b 17.57 18.18 
logβ [CuL(OH)] b 8.93 9.47 
pCu c at pH 7.4 11.35 11.50 
% [CuL(OH)] at pH 7.4 5.4 4.7 
logD7.4 +0.85
d +0.95±0.06e 
a
 Data for pKa of EDTA and its Cu(II) complex taken from Ref.[39] and logβ’5.90  = 13.89 was calculated for 
[Cu(EDTA)]
2-
. 
b
 β [CuL]
+
 = β' [CuL]
+ 
× αH, where αH = 1 + [H
+
]/Ka(HL) + [H
+
]
2
/ (Ka(HL) × Ka(H2L
+
)); [H
+
] = 
10
‒5.90
 M. Log β [CuLH]
2+
 = log β [CuL]
+
 + pKa [CuLH]
2+
. Log β [CuL(OH)] = log β [CuL]
+
 ‒ pKa [CuL]
+
. 
c
 
pCu = −log [Cu(II)] at pH 7.40, cCu(II) = cL = 1 µM.
 d Taken from Ref.[6] 
e 
Data was determined using the 
same approach as in Ref.[6].  
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Figure 7. (A) UV-vis spectra of Cu-BioTriapine in the presence of EDTA at various concentrations (the 
numbers show the EDTA-to-complex ratios) [ccomplex = 25 µM; cEDTA = 0-75 µM; pH = 5.90 (50 mM MES); T 
= 25 ˚C; I = 0.10 M (KCl); ℓ = 1.0 cm] and (B) calculated individual absorption spectra of complex species 
of Cu-BioTriapine. [ccomplex = 25 µM; pH = 2 ‒ 11.5; T = 25 ˚C; I = 0.10 M (KCl); ℓ = 1.0 cm] 
 
The apparent (conditional) formation constants (β′) for this type of complexes of 
Triapine and BioTriapine were determined by competition reactions with EDTA 
spectrophotometrically at pH 5.90. The displacement by EDTA is not instantaneous and 
it was found that during a 2 h waiting time the equilibrium state could be reached for the 
competition reaction. Representative UV-vis spectra are shown for the copper(II) 
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complex of BioTriapine in the presence of EDTA at various concentrations (Figure 7A). 
EDTA and its copper(II) complex have negligible contribution to the measured 
absorbance values in the monitored wavelength range (320–550 nm) and merely 
species [CuL]+ and HL absorb light. The increasing amount of EDTA results in decrease 
in the absorbance at the wavelength 422 nm at which the transition belongs to the 
characteristic S→Cu charge-transfer band (Figure S1B). The determined conditional 
formation constants are collected in Table 3. From these data the overall stability 
constants (β) of the complexes [CuL]+, [CuLH]2+ and [CuL(OH)] were calculated. These 
constants reveal that [CuL]+ is the predominating species at physiological pH and the 
fraction of [CuL(OH)] is low (~ 5%). The pCu (−log [Cu(II)]) values were also calculated 
using the experimentally determined equilibrium constants in order to compare the 
copper(II) binding ability of the ligands at physiological pH (Table 3), as the direct 
comparison of the logβ [CuL]+ constants is not adequate due to the somewhat different 
basicity of the ligands. All these data confirm the fairly similar solution stability of the 
copper(II) complexes of Triapine and BioTriapine. Notably, the solution stability of the 
Triapine copper(II) complex is higher in pure water compared to that showed in the 
30% (w/w) DMSO/H2O mixture, as it was expected, since DMSO can coordinate to 
copper(II) very weakly. 
The same competition reaction with EDTA was performed for the iron(III) 
complexes of Triapine and BioTriapine. However, it was found that even a 60-fold 
excess of EDTA could not replace the original ligand after 2 h, and even after 48 h only 
a minor spectral change could be detected. This finding suggests a kinetically rather 
inert character of these iron(III) complexes that hinders the accurate determination of 
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the conditional stability constants. Nevertheless, the data suggests that both iron(III) 
complexes show very high stability. The high stability was also reflected in the 
experimental finding that acidification of both iron(III) complexes down to pH 2 did not 
lead to the complex dissociation (at 20 µM concentration in pure water).  
 
Redox behavior of the copper(II) and iron(III) complexes 
Since the stability measurements did not show any significant differences between the 
copper(II) and iron(III) complexes of Triapine and BioTriapine, we performed 
electrochemical measurements to evaluate the redox behavior of the metal complexes. 
Cyclic voltammograms of Fe-Triapine, Fe-BioTriapine, Cu-Triapine and Cu-
BioTriapine were measured in DMF/PBS pH 7.4 (2:1 v/v) containing 0.10 M [n-
Bu4N][BF4] as supporting electrolyte (due to the low aqueous solubility of the 
complexes, measurements were performed in DMF/PBS mixtures). Cu-Triapine 
displayed an irreversible Cu(II)/Cu(I) reduction peak at Ep = –0.19 V versus normal 
hydrogen electrode (NHE) at 200 mV/s scan rate (in accordance with our previous 
reports[33]), while Cu-BioTriapine was reduced at Ep = –0.23 V. The slightly lower 
redox potential of Cu-BioTriapine in comparison to Cu-Triapine is in line with the 
electron donor properties of the methylene groups of the linker moiety. Interestingly, in 
contrast, both Fe-Triapine and Fe-BioTriapine have a reversible FeIII/FeII redox couple 
at E1/2 = +0.06 V. Consequently, the redox potential seems not to be a critical parameter 
when searching for distinct differences of the metal complexes. However, distinctions in 
the electrochemical properties of a compound can not only occur due to variations of 
the redox potential, but also in the kinetics of the reduction processes. Consequently, 
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we investigated the reduction behavior of the copper(II) and iron(III) complexes with the 
biologically important reducing agents ascorbic acid (AA) and glutathione (GSH). The 
reduction processes were followed for 20 min by UV-vis spectrophotometry in PBS at 
pH 7.4 using 20 eq. of reducing agent (the reducing agents itself and their oxidized 
forms mainly absorb at λ <~300 nm[40, 41], therefore the spectra are depicted in the 
range of 300–700 nm). AA practically was not able to reduce Cu-Triapine under the 
applied conditions (Figure S2A), whereas in case of Cu-BioTriapine a slow absorbance 
decrease at lmax (426 nm) was observed (Figure 8A). Therefore, both copper(II) 
complexes could not be reduced efficiently by AA under the applied conditions which is 
in agreement with literature data of copper(II)-FTSC[42]. GSH is a more powerful 
reducing agent with a lower formal potential compared to that of AA (AA; +0.06 V vs. 
NHE[43]; GSH: –0.24 V vs. NHE[43]). As expected, GSH was able to reduce both 
copper(II) complexes (Figures 8B and S2B). Notably, the first recorded spectrum after 
mixing the reactants showed a shift of the λmax value (e.g. 426 → 432 nm for Cu-
BioTriapine) most probably due to the formation of a ternary complex with GSH. 
Subsequently, a significant decrease of the absorbance was observed at this λmax, while 
the absorbance value was increased at the λmax of the free ligand (~360 nm), which 
most probably can be explained by the formation of the unstable copper(I) complex with 
subsequent dissociation of the free ligand. The reaction seems to be incomplete in both 
cases since no further changes in the spectra occurred after ~10–15 min (Figures 8B 
and S2B). To prove that a complete reduction of the copper(II) complexes indeed 
generates the free ligands, dithiothreitol (DTT) with a redox potential of –0.33 V[44] was 
used. Co-incubation with DTT resulted in complete loss of the maximum of the 
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copper(II) complex at ~420 nm and an instant formation of a new band at λmax ~360 nm, 
identical with the spectra of the free ligands (Figures 8C and S2C).  
Notably, comparison of the reduction rate of Cu-BioTriapine and Cu-Triapine in 
the presence of GSH by plotting ln(A/A0) vs. t (Figure 8D using the absorbance at 432 
nm) indicated that the reduction is slower and less complete for Cu-BioTriapine 
compared to Cu-Triapine.  
 
Figure 8. Time-dependent UV-Vis spectra of Cu-BioTriapine after addition of 20 equiv. (A) AA, (B) GSH 
and (C) DTT. (‘reference’ indicates the spectra of Cu-BioTriapine without reducing agent while ‘1 min’ 
represents the spectrum measured directly after addition of the reducing agent). (D) The ln (A/A0) values 
recorded at 432 nm were plotted against the time for the reduction of Cu-Triapine (blue line) and Cu-
BioTriapine (orange line) with 20 equiv. GSH.  
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In the case of the iron(III) complexes all three reductants were able to reduce the 
complexes, in line with the higher redox potential compared to the copper(II) complexes. 
Reduction led to the development of novel bands in the spectra at 500–650 nm being 
characteristic for the greenish iron(II) species (Figure S3A-E). In the case of the 
reduction of Fe-BioTriapine with DTT, a precipitate was formed making adequate 
monitoring of the reduction process complicated. Generally, reduction was 
instantaneous with AA and DTT, while it was somewhat slower with GSH (Figures S3B 
and S3E). Evaluation of the reduction speed with GSH revealed as in case of the 
copper(II) complexes that Fe-BioTriapine is reduced slightly slower compared to Fe-
Triapine (data not shown).  
 
H2O2 and superoxide radical formation ability of the metal complexes 
It is well-known that especially copper(II) complexes of thiosemicarbazones (including 
Cu-Triapine) are able to redox cycle with formation of H2O2 and O2
.-[33, 45], which 
could also be influenced by differences in the reduction kinetics. To examine whether 
this is applicable also for the new BioTriapine complexes, the metal complexes were 
co-incubated with AA and N-acetylcysteine (NAC) under cell-free conditions and H2O2 
levels were determined using the xylenol-based PerOXOquant assay. As depicted in 
Figure 9A, the iron complexes did not induce significant H2O2 production. In contrast, 
co-incubation of the copper complexes with NAC resulted in high levels of H2O2 
formation (~2 equiv. of H2O2 per copper complex) in line with previous data on Cu-
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Triapine[33]. As expected from the co-incubation reduction experiments co-treatment 
with AA could not generate relevant levels of H2O2.  
 
Figure 9: NAC- and AA-induced H2O2 production of (A) copper(II) and (B) iron(III) complexes of Triapine 
and BioTriapine determined using the xylenol-based PerOXOquant assay. The metal complexes were 
used at concentrations of 50 µM and the reducing agents at 2 mM (NAC) and 50 µM (AA). The results 
given are the mean ± standard deviation of three determinations. 
 
To investigate the ability of the metal complexes to generate O2
.-  upon reduction by 
NAC or AA, nitroblue tetrazolium (NBT) was used as an O2
.- detecting agent. As 
depicted in Figure 10A, distinct formation of O2
.- was detected for the copper(II) 
complexes in the presence of NAC, while in presence of AA no O2
.- formation was 
detected as expected. In case of the iron(III) complexes Fe-BioTriapine and Fe-
Triapine, both AA and NAC induced formation of O2
.- (Figure 10B), which is also in 
accordance with reduction data (Figure S3). Interestingly, O2
.-  generation by co-
incubation with AA was distinctly lower with Fe-BioTriapine than with Fe-Triapine. 
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Figure 10: O2
.-
 generation ability of (A) copper(II) and (B) iron(III) complexes of Triapine and 
BioTriapine in the presence of NAC and AA. The dependency of the level of generated O2
.-
 on NAC (2 
mM) and AA (50 µM) was determined by measuring the reduction of nitroblue tetrazolium (NTB) 
spectrophotometrically. The metal complexes were used at concentrations of 25 µM. The values given 
are the mean ± standard deviation of three determinations. 
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Discussion 
Triapine is a prominent anticancer drug candidate which has already been investigated 
in more than 30 clinical phase I and II trials[8, 10]. However, at least partially based on 
insufficient tumor accumulation, further development into clinical phase III has not been 
achieved so far[2]. Therefore, drug targeting is a very promising approach for this 
substance class to improve tumor accumulation and antitumor efficiency. In recent 
years, biotin-targeting has emerged as a prominent strategy to improve activity of 
anticancer drugs with several examples reported in literature[24, 26, 46]. Consequently, 
we synthesized novel thiosemicarbazone derivatives via biotin conjugation at the 
terminal nitrogen atom. Additionally, for the biotinylated Triapine derivative 
(BioTriapine) the respective iron(III) and copper(II) complexes were synthesized. 
Unexpectedly, subsequent in vitro activity evaluation of BioTriapine and the metal 
complexes Cu-BioTriapine and Fe-BioTriapine showed no correlation with the biotin 
uptake of the used cell lines. Furthermore, inhibition of the SMVT did not prevent 
cellular accumulation of Cu-BioTriapine. Notably, also several literature reports do not 
show a correlation of the cytotoxic activity of the biotin-conjugates and the biotin uptake 
ability[47-49]. On the other hand, in case of a gemcitabine-coumarin-biotin conjugate 
preferred uptake in a biotin receptor-positive cell line was proven by confocal 
microscopy[24]. Also a 5′-deoxy-5-fluorouridine derivative with two biotin moieties 
attached showed a good correlation with biotin uptake[46]. Analyzing the structure of 
the different conjugates, it seems that the derivatives with no or shorter linker moieties 
between the drug and the biotin carboxylic acid reveal insufficient correlations of 
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cytotoxicity and biotin uptake ability, whereas long spacers or double biotin-conjugation 
enabled biotin-dependent activity. 
In the here presented study, generally both the coordination with Cu(II) as well as Fe(III) 
strongly diminished the activity of BioTriapine much stronger compared to the non-
biotinylated Triapine. Notably, in long-term clonogenic studies the activity difference 
between Cu-BioTriapine and Cu-Triapine even increased in comparison to the results 
from 72 h experiments. Noteworthy, previous studies reported different activity changes 
of thiosemicarbazones after Cu(II) complexation, depending on the exact nature of the 
ligand and also the type of the used cell lines[32, 33]. For example, the activity of Cu-
FTSC was increased ~3-fold in comparison to free FTSC, whereas APTSC (3-
aminopyridine-2-carboxyaldehyde-4N,4N-dimethylthiosemicarbazone) showed ~15-fold 
decreased cytotoxicity after copper coordination[33]. Furthermore, copper coordination 
of 2-acetylpyridine-4,4-dimethyl-3-thiosemicarbazone and 2-acetylpyridine 4,4-dimethyl-
3-thiosemicarbazone led to ~2-fold activity increase in the SK-N-MC cell line after 24h 
[32]. Consequently, the up to ~30 fold decreased cytotoxic activity is remarkable in case 
of BioTriapine. Astonishingly, complexation of BioTriapine with iron(III) resulted in 
complete inactivation of the ligand on all tested cell lines after 72 h. This is surprising as 
previous studies on iron(III) complexes of similar thiosemicarbazones reported generally 
only slightly decreased activities of the complexes in comparison to the free ligands[34, 
50]. Further long-term cytotoxicity studies of Fe-BioTriapine resulted in an increased 
effectivity compared to the results after 72 h. However, Fe-BioTriapine was still ~30-40 
times less active than Fe-Triapine. To exclude that altered uptake is responsible for the 
decreased activity of the biotinylated derivatives, the cell uptake of Cu-BioTriapine 
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compared to Cu-Triapine was investigated by ICP-MS measurements (the Fe(III) 
complexes could not be measured due to the very high iron background). However, 
these data did not show significant differences between Cu-Triapine and Cu-
BioTriapine and therefore does not explain their strongly different cytotoxic activity. 
Consequently, we performed detailed physico- and electrochemical experiments to 
elucidate possible differences. However, neither lipophilicity or complex stability, nor the 
reduction potential or behavior in presence of reducing agents (like AA, GSH) of the 
metal complexes showed any striking differences between BioTriapine and Triapine. 
Only the reduction kinetics of the metal complexes in case of BioTriapine was slower. 
As there are several reports that copper(II) complexes of thiosemicarbazones induce 
H2O2 and superoxide formation[33, 45], we further investigated their generation in cell-
free assays. However, distinct differences in this regard were not found either between 
Cu-BioTriapine and Cu-Triapine or between Fe-BioTriapine and Fe-Triapine, except 
reduced O2
.- formation in the presence of AA in case of Fe-BioTriapine. Consequently, 
a strong contribution of altered reduction kinetics and by this formation of reactive 
oxygen species seems unlikely.  
Although the biotin-conjugated thiosemicarbazones have been extensively investigated 
in this study by physico- and electrochemical methods, the striking cytotoxic activity 
differences between the BioTriapine metal complexes and that of Triapine could 
actually not be explained by their physicochemical properties. Consequently, 
differences in their biological functionality have to underlie the observed effects. One 
hypothesis could be that in case of the BioTriapine metal complexes the intracellular 
distribution is strongly altered resulting in insufficient target inhibition. On the other 
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hand, the bulky structures of Cu-BioTriapine and especially Fe-BioTriapine can lead 
to retention of the complexes in the cell membrane which prevents effective delivery into 
the cell and results in the significantly decreased activity. This effect could not be 
excluded by the performed ICP-MS uptake studies of the copper complexes.  
Noteworthy, although the metal complexes revealed an unexpectedly low cytotoxic 
potential on cancer cell lines in vitro, BioTriapine as a metal-free ligand, showed 
significant tumor growth retardation in a CT-26 colon cancer mouse model comparable 
to Triapine. Therefore, biotin-conjugation of thiosemicarbazones is still an interesting 
strategy for future investigations. Keeping the distinct difference in the anticancer 
activity between the ethylene linker containing BioFTSC1 and butylene-linker 
compound BioFTSC2 in mind, a further increase of this linker between biotin and the 
thiosemicarbazone, e.g. even with a (mini-)PEG moiety, might be a promising option for 
structural modification in order to further increase the anticancer activity and probably 
also enable biotin-mediated selective accumulation. 
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Materials and Methods  
1a was purchased from Alfa Aesar (Germany). 1b[51], 2a[52], 3a[52], 2b[31], 3b[31], 
biotin-NHS[53], Triapine[34], Fe-Triapine[34] and Cu-Triapine[33] were synthesized 
according to literature. All other reagents and solvents were obtained from commercial 
suppliers and used without further purification. Elemental analyses were performed on a 
Perkin Elmer 2400 CHN Elemental Analyzer by the Microanalytical Laboratory of the 
University of Vienna. ESI-MS spectrometry was carried out with a Bruker HCT plus ESI-
QIT spectrometer (Bruker Daltonic, Bremen, Germany). Expected and experimental 
isotope distributions were compared. 1H and 13C NMR spectra were recorded in d6-
DMSO or D2O with a Bruker Avance III 500 MHz spectrometer at 500.10 (
1H) and 
125.75 (13C) MHz at 298 K. Chemical shifts (ppm) were referenced internal to the 
solvent residual peaks. For the description of the spin multiplicities the following 
abbreviations were used: s = singlet, d = duplet, t = triplet, q = quartet, m = multiplet.  
 
Synthesis 
 
(E)-N-(2-aminoethyl)-2-(pyridin-2-ylmethylene)hydrazine-1-carbothioamide 
dihydrochloride (4a). Compound 3a (2.15 g, 9.18 mmol) was dissolved in ethanol (40 
mL) and 2-formylpyridine (0.87 mL, 9.18 mmol) was added. The reaction mixture was 
stirred for 10 min at 90°C, concentrated HCl (3.78 mL) was added and the solution was 
refluxed for 4 h. After cooling to room temperature, the yellow precipitate was filtered 
off, washed with cold ethanol and dried in vacuo. Yield: 2.18 g (80 %). ESI-MS in 
methanol (positive): m/z 224 [M+H]+. 1H NMR (D2O): δ = 8.67 (d, 
3J = 5 Hz, 1H, Hpy), 
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8.48 (t, 3J = 7 Hz, 1H, Hpy), 8.10 (d, 
3J = 8 Hz, 1H, Hpy), 8.07 (s, 1H, HC=N), 7.89 (t, 
3J = 
8 Hz, 1H, Hpy), 3.99 (t,
 3J = 6 Hz, 2H, NHCH2), 3.28 (t, 
3J = 6 Hz, 2H, NHCH2) ppm. 
13C 
NMR (D2O): δ 178.7 (C=S), 147.1 (Cpy), 145.5 (Cq, py), 142.3 (Cpy), 133.4 (HC=N), 126.9 
(Cpy), 126.8 (Cpy), 41.2 (NHCH2), 39.0 (CH2NH2). 
 
(E)-N-(4-aminobutyl)-2-(pyridin-2-ylmethylene)hydrazine-1-carbothioamide 
dihydrochloride (4b). Compound 3b (0.30 g, 1.14 mmol) was dissolved in ethanol (4 
mL) and 2-formylpyridine (0.11 mL, 1.14 mmol) was added. The reaction mixture was 
stirred for 10 min at 90°C, concentrated HCl (0.47 mL) was added and the solution was 
refluxed for 4 h. After cooling to room temperature, the solution was stored at 4°C 
overnight. The yellow precipitate was filtered, washed with cold ethanol and dried in 
vacuo. Yield: 0.34 g (92 %). ESI-MS in methanol (positive): m/z 252 [M+H]+. 1H NMR 
(D2O): δ = 8.69 (d, 
3J = 6 Hz, 1H, Hpy), 8.51 (ddd, 
3J = 8 Hz, 3J = 8 Hz, 4J = 2 Hz, 1H, 
Hpy), 8.11 (d, 
3J = 8 Hz, 1H, Hpy), 8.07 (s, 1H, HC=N), 7.93–7.90 (m, 1H, Hpy), 3.69 (t, 
3J 
= 7 Hz, 2H, NHCH2), 3.02 (t, 
3J = 7 Hz, 2H, NHCH2), 1.78–1.67 (m, 4H, CH2(CH2)2CH2) 
ppm. 13C NMR (D2O): δ 176.9 (C=S), 146.8 (Cpy), 145.6 (Cq, py), 142.3 (Cpy), 133.1 
(HC=N), 126.7 (Cpy), 126.6 (Cpy), 43.5 (NHCH2), 39.1 (CH2NH2), 25.2 (-CH2-), 24.0 (-
CH2-) ppm. 
 
 
(E)-N-(4-aminobutyl)-2-((3-aminopyridin-2-yl)methylene)hydrazine-1-
carbothioamide dihydrochloride (4c). (2-formyl-pyridin-3-yl)-carbamic acid tert-butyl 
ester (0.51 g, 2.28 mmol) and concentrated HCl (0.6 mL) were added to a solution of 
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compound 3b (0.60 g, 2.28 mmol) in ethanol (12 mL). The solution was refluxed for 4 h 
and after cooling to room temperature the orange precipitate was filtered, washed with 
cold ethanol and dried in vacuo. Yield: 0.61 g (79 %). ESI-MS in methanol (positive): 
m/z 267 [M+H]+.  1H NMR (D2O): δ = 8.22 (s, 1H, HC=N), 7.99 (dd, 
2J = 4 Hz, 3J = 1 Hz, 
1H, Hpy), 7.78 (d, 
3J = 9 Hz, 1H, Hpy), 7.60 (dd, 
2J = 9 Hz, 3J = 5 Hz, 1H, Hpy), 3.67 (t,
 3J 
= 6 Hz, 2H, NHCH2), 3.01 (t,
 3J = 7 Hz, 2H, CH2NH), 1.76–1.66 (m, 4H, CH2(CH2)2CH2) 
ppm. 13C NMR (D2O): δ 176.5 (C=S), 145.7 (Cq, py), 134.5 (HC=N), 132.1 (Cpy), 131.1 
(Cpy), 126.6 (Cpy), 126.5 (Cpy) 43.6 (NHCH2), 39.2 (CH2NH2), 25.4 (-CH2-), 24.0 (-CH2-) 
ppm. 
 
(E)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-N-(2-(2-(pyridin-2-
ylmethylene)hydrazine-1-carbothioamido)ethyl)pentanamide (BioFTSC1). A 
solution of biotin-NHS (0.10 g, 0.29 mmol) in abs. DMF (3 mL) was added to a 
suspension of 4a (0.09 g, 0.29 mmol) and Et3N (0.12 mL, 0.87 mmol) in abs. DMF (2 
mL). After stirring of the reaction mixture overnight, water (15 mL) was added and the 
mixture was stored at +4°C for 15 min. Subsequently, the white precipitate was filtered 
off, washed with water/isopropanol (1:1 v/v) and dried in vacuo. The product was 
recrystallized from water. Yield: 0.18 g (66 %). Anal. Calcd for C19H27N7O2S2∙H2O 
(Mr = 467.61 g/mol): C, 48.80; H, 6.25; N, 20.97; S, 13.71. Found: C, 48.61; H, 6.19; N, 
20.86; S, 13.55. ESI-MS in methanol (positive): m/z 450, [M+H]+. 1H NMR (500.10 MHz, 
DMSO-d6): δ 11.76 (s, 1H, (C=N)NH), 8.81 (t, 
3J = 5 Hz, 1H, (C=S)NHCH2), 8.60–8.55 
(m, 1H, Hpy), 8.38 (d, 
3J = 6 Hz, 1H, Hpy), 8.10–8.06 (m, 2H, HC=N and CH2NHC=O), 
7.86 (ddd, 3J = 8 Hz,  3J = 8 Hz,  4J = 2 Hz, 1H, Hpy), 7.39 (ddd, 
3J = 7 Hz,  3J = 5 Hz,  4J 
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= 1 Hz, 1H, Hpy), 6.40 (s, 1H, HN(C=O)NH), 6.35 (s, 1H, HN(C=O)NH), 4.30–4.26 (m, 
1H, HC-CH), 4.10–4.06 (m, 1H, HC-CH), 3.62–3.56 (m, 2H, (C=S)NHCH2CH2NH), 3.35 
(2H, (C=S)NHCH2CH2NH, partially below the water signal), 3.06–3.00 (m, 1H, CHS), 
2.79 (dd, 2J = 12 Hz, 3J = 5 Hz, 1H, SCH2), 2.55 (d, 
2J = 12 Hz, 1H, SCH2), 2.12 (t, 
3J = 
7 Hz, 2H, (C=O)CH2CH2CH2CH2), 1.62–1.23 (m, 6H, (C=O)CH2CH2CH2CH2) ppm. 
13C 
NMR (125.81 MHz, DMSO-d6): δ 178.0 (C=S), 173.6 (NH(C=O)CH2), 163.2 
(HN(C=O)NH), 153.9 (Cq, py), 149.8 (Cpy), 142.7 (HC=N), 136.9 (Cpy), 124.6 (Cpy), 120.7 
(Cpy), 61.5 (HC-CH), 59.6 (HC-CH), 55.8 (CHS), 45.0 ((C=S)NHCH2CH2NH), 40.0 (S-
CH2), 38.2 ((C=S)NHCH2CH2NH), 35.6 ((C=O)CH2CH2CH2CH2), 28.6, 28.5 and 25.6 
((C=O)CH2CH2CH2CH2). 
 
(E)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-N-(4-(2-(pyridin-2-
ylmethylene)hydrazine-1-carbothioamido)butyl)pentanamide (BioFTSC2). A 
solution of Biotin-NHS (0.20 g, 0.58 mmol) in abs. DMF (3 mL) was added to a 
suspension of 4b (0.19 g, 0.58 mmol) and Et3N (0.24 mL, 1.74 mmol) in abs. DMF (3 
mL) and the reaction mixture was stirred overnight. Water (25 mL) was added and the 
white precipitate was filtered off, washed with water and dried in vacuo. The product 
was recrystallized from water. Yield: 0.23 g (80 %). Anal. Calcd for 
C21H31N7O2S2∙0.5H2O (Mr = 486.66 g/mol): C, 51.83; H, 6.63; N, 20.15; S, 13.18. 
Found: C, 51.55; H, 6.68; N, 20.14; S, 13.00. ESI-MS in methanol (positive): m/z 478, 
[M+H]+. 1H NMR (500.10 MHz, DMSO-d6): δ 11.65 (s, 1H, (C=N)NH), 8.69 (t, 
3J = 6 Hz, 
1H, (C=S)NHCH2), 8.59–8.56 (m, 1H, Hpy), 8.28 (d,
 3J = 8 Hz,  1H, Hpy), 8.10 (s, 1H, 
HC=N), 7.88–7.83 (ddd, 3J = 8 Hz, 3J = 8 Hz, 4J = 2 Hz, 1H, Hpy), 7.78 (t, 
3J = 6 Hz, 1H, 
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HN(C=O)CH2), 7.41–7.37 (ddd, 
3J = 7 Hz, 3J = 5 Hz, 4J = 1 Hz, 1H, Hpy), 6.41 (s, 1H, 
HN(C=O)NH), 6.35 (s, 1H, HN(C=O)NH), 4.33–4.28 (m, 1H, HC-CH), 4.15–4.11 (m, 1H, 
HC-CH), 3.61–3.55 (m, 2H, (C=S)NHCH2), 3.13–3.05 (m, 3H, CH2NH(C=O) and CHS), 
2.82 (dd, 2J = 13 Hz, 3J = 5 Hz, 1H, SCH2), 2.58 (d, 
2J = 12 Hz, 1H, SCH2), 2.06 (t,
 3J = 
7 Hz,  2H, (C=O)CH2), 1.62–1.23 (m, 10H, (C=O)CH2CH2CH2CH2 and 
HNCH2CH2CH2CH2NH) ppm. 
13C NMR (125.81 MHz, DMSO-d6): δ 177.6 (C=S), 172.3 
(CH2NH(C=O)), 163.2 (HN(C=O)NH), 153.5 (Cq, py), 149.5 (Cpy), 142.1 (HC=N), 137.4 
(Cpy), 124.6 (Cpy), 120.9 (Cpy), 61.5 (HC-CH), 59.7 (HC-CH), 55.9 (CHS), 43.8 
((C=S)NHCH2), 40.1 (SCH2), 38.7 (CH2NH(C=O)), 35.7 ((C=O)CH2), 28.7, 28.5 and 
25.8 ((C=O)CH2CH2CH2CH2), 27.2 and 26.9 ((C=S)NHCH2CH2CH2CH2NH). 
 
(E)-N-(4-(2-((3-aminopyridin-2-yl)methylene)hydrazine-1-carbothioamido)butyl)-5-
(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide (BioTriapine). Biotin-
NHS (0.30 g, 0.88 mmol) was added portionwise to a suspension of 4c (0.30 g, 0.88 
mmol) and Et3N (0.37 mL, 2.64 mmol) in 9 mL abs. DMF and the reaction mixture was 
stirred overnight. Water (46 mL) was added and the pale yellow precipitate was filtered 
off, washed with water and dried in vacuo. Yield: 0.37 g (84 %). Anal. Calcd for 
C21H32N8O2S2∙H2O (Mr = 510.68 g/mol): C, 49.39; H, 6.71; N, 21.94; S, 12.56. Found: C, 
49.61; H, 6.64; N, 21.51; S, 12.53. ESI-MS in methanol (positive): m/z 493, [M+H]+. 1H 
NMR (500.10 MHz, DMSO-d6): δ 11.29 (s, 1H, (C=N)NH), 8.37 (t,
 3J = 5 Hz, 1H, 
(C=S)NHCH2), 8.34 (s, 1H, HC=N), 7.85 (dd, 
2J = 4 Hz, 3J = 1 Hz, 1H, Hpy), 7.78 (t,
 3J = 
6 Hz, 1H, NHC=O), 7.17 (dd, 2J = 7 Hz, 3J = 1 Hz, 1H, Hpy), 7.09 (dd,
 2J = 8 Hz, 3J = 4 
Hz, 1H, Hpy), 6.45 (s, 2H, NH2), 6.42 (s, 1H, HN(C=O)NH), 6.35 (s, 1H, HN(C=O)NH), 
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4.33–4.28 (m, 1H, HC-CH), 4.15–4.11 (m, 1H, HC-CH), 3.60–3.53 (m, 2H, 
(C=S)NHCH2), 3.12–3.04 (m, 3H, CH2NHC=O and CHS), 2.82 (dd, 
2J = 12 Hz, 3J = 5 
Hz, 1H, SCH2), 2.58 (d, 
2J = 12 Hz, 1H, SCH2), 2.06 (t,
 3J = 7 Hz,  2H, NH(C=O)CH2), 
1.66–1.24 (m, 10H, (C=O)CH2CH2CH2CH2 and HNCH2CH2CH2CH2NH) ppm. 
13C NMR 
(125.81 MHz, DMSO-d6): δ 176.8 (C=S), 172.3 (NH(C=O)CH2), 163.2 (HN(C=O)NH), 
148.4 (HC=N), 144.4 (Cq, py), 137.3 (Cpy), 133.1 (Cq, py), 125.0 (Cpy), 123.2 (Cpy), 61.5 
(HC-CH), 59.7 (HC-CH), 55.9 (CHS), 44.0 ((C=S)HNCH2), 40.1 (SCH2), 38.8 
(CH2NHC=O), 35.7 (NH(C=O)CH2), 28.7, 28.5 and 25.8 ((C=O)CH2CH2CH2CH2), 27.2 
and 27.1 ((C=S)HNCH2CH2CH2CH2NH). 
 
(E)-N-(4-(2-((3-aminopyridin-2-yl)methylene)hydrazine-1-carbothioamido)butyl)-5-
(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide-N,N,S-
dichloridocopper(II), [Cu(BioTriapine)Cl2]·H2O. To BioTriapine (50 mg, 0.102 mmol) 
dissolved in hot methanol (5 mL), copper(II)chloride dihydrate (17 mg, 0.102 mmol) in 
methanol (0.5 mL) was added dropwise, and the reaction mixture was stirred for 2 h at 
room temperature. The green precipitate was filtered off, washed with methanol and 
diethyl ether, and dried in vacuo. Yield: 53 mg (81 %). Anal. Calcd for 
CuC21H32N8O2S2Cl2∙H2O (Mr = 645,13 g/mol): C, 39.10; H, 5.31; N, 17.37; S, 9.94. 
Found: C, 39.37; H, 5.28; N, 17.03; S, 9.97. ESI-MS in methanol (positive): m/z 554, [M-
2Cl-H]+ ESI-MS in methanol (negative): m/z 588, [M-2H-Cl]-; m/z 624, [M-H]-. 
 
[Bis(E)-N-(4-(2-((3-aminopyridin-2-yl)methylene)hydrazine-1-
carbothioamido)butyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamide-N,N,S-iron(III)] nitrate, [Fe(BioTriapine)2]NO3·3.5H2O. To 
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BioTriapine (80 mg, 0.162 mmol) and N-methylmorpholine (18 μL, 0.161 mmol) in 
methanol (3.5 mL) iron(III) nitrate nonahydrate (33 mg, 0.81 mmol) in methanol (0.5 mL) 
was added dropwise and the reaction mixture was stirred for 2 h at room temperature. 
After addition of ethyl acetate (5 mL), the dark brown precipitate was filtered off, washed 
with ethyl acetate and dried in vacuo. The crude product was taken up in methanol and 
purification by preparative RP-HPLC using a Waters XBridge C18 column on an Agilent 
1200 Series system yielding a brown solid (Milli-Q water and acetonitrile were used as 
eluents). Yield: 22 mg (42 %). Anal. Calcd for FeC42H62N17O7S4∙3.5H2O (Mr = 1164,21 
g/mol): C, 43.33; H, 5.97; N, 20.45; S, 11.02. Found: C, 43.66; H, 5.77; N, 20.05; S, 
10.96. ESI-MS in methanol (positive): m/z 1038, [M]+.  
 
Electrochemistry 
Cyclic voltammograms were measured in a three-electrode cell using a 2.0-mm-
diameter glassy carbon working electrode, a platinum auxiliary electrode and an 
Ag/AgCl reference electrode containing 3.0 M NaCl. Measurements were performed at 
room temperature using EG & G PARC 273A potentiostat/galvanostat. Deaeration of 
solutions was accomplished by passing a stream of argon through the solution for 5 min 
prior to measurement and then maintaining blanket atmosphere of argon over the 
solution during measurement. The potentials were measured in DMF/phosphate-
buffered saline (PBS) pH 7.4 (2:1 v/v) containing 0.10 M [n-Bu4N][BF4] and are quoted 
relative to the normal hydrogen electrode (NHE). To convert the obtained potentials (vs. 
Ag/AgCl) to values vs. NHE, +0.209 V was added to the measured results. 
 
Spectrophotometric titrations  
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A Hewlett Packard 8452A diode array spectrophotometer was used to record the UV-
Vis spectra in the interval 200–800 nm. The path length was 1 cm. Proton dissociation 
constants (pKa) of the ligands, the copper(II) mono complexes and the individual 
spectra of the species in the various protonation states were calculated by the computer 
program PSEQUAD[54]. Spectrophotometric titrations were performed on samples 
containing the ligands or complexes at 25-75 µM concentration by a KOH solution in the 
presence of 0.1 M KCl at 25.0 ± 0.1 °C in the pH range from 2.0 to 11.9. An Orion 710A 
pH-meter equipped with a Metrohm combined electrode (type 6.0234.100) and a 
Metrohm 665 Dosimat burette were used for the pH-metric titrations. The electrode 
system was calibrated to the pH = log[H+] scale by means of blank titrations (HCl vs. 
KOH) according to the method suggested by Irving et al.[55]. The average water 
ionization constant (pKw) is 13.76 ± 0.05 in water. Argon was also passed over the 
solutions during the titrations. 
The conditional stability constants (β’) of the copper(II) complexes were 
calculated at pH 5.90 based on the spectral changes via the displacement reaction with 
EDTA in the presence 50 mM 2-(N-morpholino)ethanesulfonic acid (MES) and 0.1 M 
KCl. In the competition experiments the samples contained 25 µM copper(II), 25 µM 
ligand and the concentration of EDTA was varied in the range from 0 to 100 µM. The 
conditional stability constants of the metal complexes (β' (CuL)) and the individual 
spectra of the species were calculated by the computer program PSEQUAD[54]. The 
overall stability constants of the [CuL]+ complexes (β) were calculated from the 
conditional stability constants: β [CuL]+ = β ' [CuL]+ × αH, where αH = 1 + [H
+]/Ka (HL) + 
[H+]2 / (Ka (HL) × Ka (H2L
+)); [H+] = 10‒5.90 M. The overall stability constants of the 
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protonated [CuLH]2+ and the mixed hydroxido [CuL(OH)] complexes were calculated as 
follows: log β [CuLH]2+ = log β [CuL]+ + pKa [CuLH]
2+. Log β [CuL(OH)] = log β [CuL]+ ‒ 
pKa [CuL]
+. 
 
Spectrophotometric reduction kinetic measurements 
The redox reactions of the metal complexes (with concentrations of 50 µM in PBS pH 
7.4) with 20 equivalents AA, GSH and DTT were studied on a Perkin Elmer lambda 35 
spectrophotometer with a PTP 6 (Peltier Temperature Programmer) and Julabo AWC 
100 recirculating cooler at 25°C. Spectra were recorded before and after addition of the 
reducing agents and changes were followed for 20 min. 
 
Cell culture 
The following human cancer cell lines were used in this study: The colorectal 
carcinoma-derived cell lines HCT116 and CT26 as well as the breast cancer cell lines 
SKBR-3, MCF-7, and MDA-MB-231. All cell lines were grown in Dulbecco's Modified 
Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37°C and 
5% CO2, with the exception of HCT116, which were grown in McCoy’s medium 
supplemented with 2 mM glutamine and 10%FBS and CT26 grown in DMEM/F-12 
supplemented with 10% FCS. In addition, the non-malignant fibroblasts HLF (in 
RPMI1640 with 10% FCS) and keratinocytes HACAT (in DMEM with 10% FCS) were 
tested. All cells were purchased from ATCC and regularly checked for Mycoplasma 
contamination. 
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Cellular biotin uptake 
Cells (5 x 105 cells/mL in 1 mL growth medium per well) were seeded in 6-well plates 
and allowed to attach for 24 h. Then, growth medium was replaced with 2 mL serum-
free medium (RPMI 1640) per well. On the following day, the cells were treated with 25 
mM FITC-labeled biotin. After 6 h incubation, cells were washed twice with phosphate-
buffered saline (PBS) and collected by trypsinisation. The suspension was centrifuged 
for 5 min at 1200 rpm at 4°C and the supernatant discarded. For flow cytometry, the 
cells were re-suspended in PBS containing 78.1 mM Na2PO4 x 2H2O, 14.7 mM KH2PO4, 
26.8 mM KCl and 1.37 M NaCl, followed by analyses of the intracellular fluorescence 
levels (FITC) measured by LSRFortessa flow cytometer (BD Biosciences, New Jersey, 
USA) and further analyzed using Flowing Software (University of Turku, Finland) to 
quantify the intracellular fluorescent units. 
 
Cell viability assay 
To determine cell viability, depending on the cell line, 2-5 x 104 cells/mL were seeded in 
96-well plates (100 µL/well) and allowed to recover for 24 h. Then, cells were exposed 
to the drugs for the indicated concentrations for 72 h. Anticancer activity was measured 
by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-based vitality 
assay following the manufacturer’s recommendations (EZ4U, Biomedica, Vienna, 
Austria). Cell viability was calculated using the Graph Pad Prism software (using a 
point-to-point function) and was expressed as IC50 values calculated from full dose-
response curves (drug concentrations inducing a 50% reduction of cell number in 
comparison to untreated control cells cultured in parallel). 
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ICP-MS 
To determine cellular accumulation of the Cu-containing drugs, cells were incubated 
with 25 µM and 50 μM of the copper complexes and copper(II) chloride for 4 h at 37 °C, 
washed twice with PBS and then lysed in 500 μL of tetramethylammonium hydroxide at 
room temperature for 5 min. The obtained lysates were dissolved in 25 mL 0.6 M HNO3. 
Copper concentrations were determined using an Agilent ICP-MS 7900 (Agilent 
Technologies, Santa Clara, CA).  
 
Long-term cell viability (Clonogenic assay) 
To examine long time cell viability, 1 x 103 cells/mL of HCT116 and 2 x 103 cells/mL of 
MCF-7 were seeded in 24-well plates (500 µL/well) and allowed to recover for 24 h. 
Then, cells were exposed to the drugs (100 µL/well) for the indicated concentrations for 
9 days. After incubation, the medium was removed and the wells dried overnight. The 
following day, the cells were washed once with 300 µL PBS per well and were then 
fixed with 300 µL methanol per well. Afterwards, cells were stained with crystal violet, 
washed with water and dried overnight. Grey scaled pictures of the wells were made by 
scans using a Typhoon machine. The anticancer activity was measured by analyzing 
these pictures with ImageJ.  
 
Animals 
Eight- to twelve-week-old Balb/c mice were purchased from Harlan (Italy) and were 
housed under standard conditions with a 12 h light-dark cycle at the animal research 
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facility with ad libitum access to food and water. The experiments were performed 
according to the Federation of Laboratory Animal Science Association guidelines for the 
use of experimental animals and were approved by the Ethics Committee for the Care 
and Use of Laboratory Animals at the Medical University Vienna and the Ministry of 
Science and Research, Austria (BMWF-66.009/0084-II/3b/2013). With regard to the 
execution of our animal experiments, we followed the ARRIVE guidelines. 
 
CT26 experiment in vivo 
The anticancer activity of BioTriapine was investigated in vivo using murine colon 
cancer cells (CT-26). For this, 5 x 105 cells in 50 µL were injected subcutaneously into 
the right flank of the mice. When tumor nodules were palpable, animals were treated 
orally with BioTriapine (25 mg/kg in 10% DMSO) on 5 subsequent days for two cycles. 
Body weight and tumor growth were measured every second day using a micro-caliper. 
Tumor size was assessed by caliper measurement and tumor volume calculated using 
the formula: (length x width2)/2.  
 
Generation of superoxide radicals and H2O2 formation assays 
To examine cell-free production of H2O2, the PerOXO-quant assay (Pierce, Rockford, 
IL, USA) was used according to the manufacturer’s recommendations and as described 
previously [33]. For investigation of the cell-free production of superoxide radicals of the 
complexes, the reduction of NBT was analyzed as described in our previous 
publication[33]. 
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Abbreviations: AA: ascorbic acid; APTSC: 3-aminopyridine-2-carboxyaldehyde-4N,4N-
dimethylthiosemicarbazone; BioFTSC1: (E)-5-(2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)-N-(2-(2-(pyridin-2-ylmethylene)hydrazine-1-
carbothioamido)ethyl)pentanamide; BioFTSC2: (E)-5-(2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)-N-(4-(2-(pyridin-2-ylmethylene)hydrazine-1-
carbothioamido)butyl)pentanamide; BioTriapine: (E)-N-(4-(2-((3-aminopyridin-2-
yl)methylene)hydrazine-1-carbothioamido)butyl)-5-(2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamide; DMF: dimethylformamide; DMSO: dimethyl sulfoxide; 
DTT: dithiothreitol; ESI: electrospray ionization; FTSC: 2-formylpyridine 
thiosemicarbazone; GSH: glutathione; NBT: nitro blue tetrazolium; NAC: N-
acetylcysteine; NHE: normal hydrogen electrode; PBS: phosphate-buffered saline; RR: 
ribonucleotide reductase; SMVT: sodium-dependent multivitamin transporter.  
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